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ABSTRACT 
GSTM1 and GSTT1 gene polymorphisms have been studied in many populations to evaluate their association 
with prostate cancer risk with contrasting results. The current study was aimed to find out the association of 
GSTM1 and GSTT1 gene polymorphisms with prostate cancer in Pakistani men. This case control study included 
pathologically confirmed prostate cancer patients and age matched male controls. Epidemiological data was col-
lected by a standard questionnaire and presence or absence of GSTM1 and GSTT1 gene was observed by multi-
plex PCR using CYP1A1 as housekeeping gene. Prostate cancer was more prevalent in age of >60 years and 
most of the patients were at stage IV (70 %) and have undergone surgery. Family history of cancer, smoking, 
metastasis and surgery were found to be significant (P<0.05) risk factors in prostate cancer development. 
Gleason score 7 was most prevalent (40.5 %) in prostate cancer patients. Source of drinking water, residential 
area, occupation, eating habits and number of family members had no association (P>0.05) with prostate cancer 
risk. No significant association was found when comparing GSTM1 (OR=0.78) and GSTT1 (OR=0.89) gene de-
letions with prostate cancer risk. Smoking and TNM staging were also not associated with deletion of GSTM1 
and GSTT1 genes. Comparison of dual null deletion of both genes with prostate cancer also showed non-
significant associations. Deletion of GSTM1 gene at stage IV prostate cancer patients was significantly higher 
compared with other stages of cancer while no significance was shown by GSTT1 gene deletion. GSTM1, GSTT1 
and deletion of both GSTM1 and GSTT1 genes do not contribute towards increased risk of prostate cancer in 
Pakistani population. 
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INTRODUCTION 
Prostate cancer is one of the most com-
monly diagnosed cancer in the Western 
world. The incidence rate of prostate cancer 
reported among Asians is much lower as 
compared to Americans (Yang et al., 2013). 
In Pakistan it is the third frequent malignan-
cy in males and the diagnostic and therapeu-
tic facilities of such a prevalent cancer are 
limited in our country (Ahmad et al., 2009). 
In order to understand the biology of prostate 
cancer and develop new interventions, com-
plete analysis of different risk factors along 
with their comparison with genetics is essen-
tial (Hoffman, 2011).  
Epidemiological data suggested that age, 
smoking, dietary habits, genetics and many 
other factors may be involved in prostate 
cancer development. Age plays an important 
role in the development of prostate cancer 
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and its incidence increases with the increased 
age. An abrupt increase in the prostate can-
cer cases was observed in the last two to 
three decades in Pakistan because of in-
creased industrialization and urbanization 
(Mahmood et al., 2012). Common symptoms 
for prostate cancer includes frequent urina-
tion, dysuria, hematuria, nocturia and diffi-
culty in maintaining steady urine stream 
(Cramer et al., 2007). 
Glutathione S-transferases (GSTs) are 
detoxifying enzymes and play an important 
role in the detoxification of a number of exo-
genous and endogenous carcinogens by con-
jugation with glutathione (Agalliu et al., 
2006). Deletion of GSTM1 and GSTT1 genes 
leads to failure of the expression of GST pro-
teins, which may cause reduced detoxifica-
tion of potential carcinogens and lead to 
greater vulnerability to cancer (Spurdle et al., 
2001).  
Recently, several studies have evaluated 
the association of GSTM1 and GSTT1 with 
prostate cancer but inconsistency is observed 
in the results (Albertsen et al., 2005; Hu et 
al., 2013; Yang et al., 2013). However no 
specific data is available for Pakistani popu-
lation regarding their genetic status. There-
fore, current study is aimed to evaluate the 
xenobiotic metabolizing gene expression 
(GSTM1 and GSTT1) at DNA level and find 
out their correlation with progression of 
prostate cancer along with environmental 
risk factors.  
 
MATERIALS AND METHODS 
This case control study was conducted 
over a period of 12 months and included 350 
prostate cancer patients and 300 controls. 
Blood sample from already diagnosed and 
undergoing treatment prostate cancer pa-
tients were collected from Benazir Bhutto 
Shaheed Hospital, Rawalpindi, Shifa Interna-
tional Hospital, Urology department, Islama-
bad, Nuclear Medicine Oncology and Radio-
therapy Institute, Islamabad and Institute of 
Nuclear Medicine and Oncology Lahore. 
Whereas control samples were collected 
from general population from Lahore, Ra-
walpindi and Islamabad.  
Inclusion criteria for cases was histologi-
cally diagnosed and confirmed by oncolo-
gists as prostate cancer patients with Gleason 
scores 5-10 and for controls it was that the 
individuals should be cancer free normal at 
the time of sampling and they should not 
have any family history of cancer and PSA 
level was normal (PSA < 4 ng/dl). Epidemio-
logical data was collected by a standard 
questionnaire. Study was approved from the 
ethical committees of university as well as 
hospitals. Informed consent was taken from 
controls and patients before collecting any 
type of information or sample. DNA was ex-
tracted from lymphocytes by using phenol 
chloroform method and GSTM1 and GSTT1 
was analyzed by multiplex PCR (Masood et 
al., 2011). PCR product was run on 2 % aga-
rose gel and visualized in gel documentation 
system. Gels were read by two technicians 
blind folded to each others decision. Statisti-
cal analysis was performed by using SPSS 
software.  
 
RESULTS 
Environmental factors 
The mean age of prostate cancer patients 
was 67 (+11.3) years while that of controls 
was 64.3 (+14.17) years. The disease was 
more common (86 % patients) in age of >60 
years. About 8 % patients had family history 
of cancer (11 patients father, 9 patients 
grandfather and 8 patients brother had pros-
tate cancer). As far as general symptoms as-
sociated with prostate cancer were con-
cerned, 96 % patients had lower urinary tract 
symptoms (LUTS) voiding, urgency and 
pain in lower back showing significant asso-
ciation with prostate cancer (p<0.05). Signif-
icantly increased (p<0.05) levels of PSA 
were observed among approximately 90 % 
prostate cancer (CaP) patients. More than 
40 % patients had bone ache and hematuria 
while 10 % patients were victim of fever, 
nocturia and sleep apnea as well. Prostate 
cancer patients were belonging to different 
occupations i.e., 30 % were living a retired 
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life, 20 % were farmers, 10 % were bankers 
and 8 % were taxi drivers. Remaining 32 % 
prostate cancer patients were working in var-
ious fields like engineering, education, army 
or business persons. It was found that inci-
dence of prostate cancer was not significant-
ly (p>0.05) associated with any specific oc-
cupation. Family history of cancer (p=0.03), 
naswar chewing (p=0.01), cigarette 
(p=0.001) and huqqa smoking (p=0.02) were 
found to be significant risk factors in pros-
tate cancer development. Gleason score 7 
was (40.5 %) more common in prostate can-
cer patients. Source of drinking water, resi-
dential area, occupation, eating habits and 
number of family members had no associa-
tion (p>0.05) with prostate cancer risk. 
 
GSTM1 deletion 
GSTM1 was deleted among 46 % control 
and 52 % prostate cancer patients (Figure 1). 
No significant association was found when 
comparing GSTM1 gene deletions (OR 0.78, 
CI; 0.3-1.5) with risk of prostate cancer. Sta-
tistically significant (OR 11.11; CI 3.0-40.3) 
number of the patients were at stage IV of 
prostate cancer and showed GSTM1 gene 
deletion when compared with stage I and III. 
The results showed no significant association 
of GSTM1 (p=0.77) deletion with smoking.  
 
GSTT1 deletion 
It was found that GSTT1 gene deletion 
was less in patients and controls as compared 
with GSTM1 (Figure 1). GSTT1 gene dele-
tion was found to be non-significantly asso-
ciated with prostate cancer risk (OR=0.89; 
CI 0.6-1.2). The results showed no signifi-
cant association of GSTT1 deletion (p=0.81) 
with smoking.  
 
Both GSTM1 and GSTT1 deletions 
Null deletion of both GSTM1 and GSTT1 
was found in 20 % and 22 % control popula-
tion and prostate cancer cases respectively. 
The results show no significant association 
of both GSTM1 and GSTT1 deletion 
(OR=0.9; CI 0.6-1.3). Even no association 
was observed among the deletion of both 
genes (p=0.80) with smoking (Table 1).  
 
(a) 
(b) 
Figure 1: PCR products of prostate cancer patients run on 2 % agarose gel. Arrows indicate presence 
or deletion of GSTM1 and GSTT1 genes among controls (a) and prostate cancer patients (b). 
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Table 1: GST genotypes and prostate cancer susceptibility 
Genotypes  Patients (n) 
350 
Control (n) 
300 
OR (95% CI) P value Chi 
square 
GSTM1 
Present 
Null  
 
168 
182 
 
161 
139 
 
0.78 
(0.3-1.5) 
 
0.14 
 
2.07 
GSTT1 
Present  
Null 
 
272 
78 
 
239 
61 
 
0.89 
(0.6-1.2) 
 
0.54 
 
0.36 
Both GSTM1 & GSTT1 
Present 
Null 
 
274 
76 
 
240 
60 
 
0.9 
(0.6-1.3) 
 
0.59 
 
 
0.28 
 
 
 
DISCUSSION 
It was found that occurrence of prostate 
cancer increases many times with increased 
age as reported in populations of Africa, UK, 
America, Australia, India and Pakistan 
(Bhurgri et al., 2009). No significant associa-
tion of prostate cancer with occupation was 
found (Choubey et al., 2012) whereas pros-
tate cancer and smoking were found to be 
strongly associated in this study as well as in 
African, Americans and Chinese populations 
(Leitzmann and Rohrmann, 2012; Islami et 
al., 2014). Such cases were also reported 
where number of cigarettes smoked per day 
were significantly associated with onset and 
proliferation of prostatic carcinoma. Both 
environment and genetics were involved in 
prostate cancer development. Various envi-
ronmental constituents weaken the immune 
system and played an important role in the 
proliferation of cancer. A study conducted in 
two different islands Guadeloupe and Marti-
nique by Belpomme in 2009 revealed that 
development of prostate cancer was inde-
pendent of change in mens life style 
(Belpomme et al., 2009). 
Glutathione S-transferases were the most 
commonly studied antioxidant enzymes 
which were involved in the detoxification of 
various carcinogens and reactive oxygen 
species. Any change in these enzymes 
caused the loss of complete enzymatic activi-
ty. Hence, individuals were at greater risk 
towards the development of prostatic carci-
noma (Mo et al., 2009).  
No association was observed between 
GSTM1 deletion and prostate cancer. Similar 
results have frequently been reported in 
South Indian, Japanese, American and Afri-
cans populations (Caceres et al., 2005). 
GSTT1 deletion was not associated with 
prostate cancer in the current study and in 
Asian, Caucasian, Korean, African and 
American men (Cai et al., 2014). Dual null 
deletion of GSTM1 and GSTT1 were not as-
sociated with prostate cancer and similar re-
sults had been found in studies of African 
descent, Brazilian and Caucasians (Lavender 
et al., 2009). Therefore, these two genes vary 
ethnically and geographically. Another meta-
analysis showed no association of these two 
genes with the development of prostate can-
cer (Ntais et al., 2005).  
No significant association was found be-
tween the deletion of GSTM1 and prostate 
cancer among smokers. Similar kind of re-
sults were revealed among Asians, North In-
dians and Chileans (Mittal et al., 2004; Ca-
ceres et al., 2005; Silig et al., 2006; Wei et 
al., 2012). 
GSTT1 deletion was also not associated 
with prostatic carcinoma among smokers. It 
was reported that GSTT1 deletion and pros-
tate cancer were not associated among 
smokers in Turkish, Finnish and Indian pop-
ulations (Kidd et al., 2003; Mittal et al., 
2004; Silig et al., 2006). 
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CONCLUSION 
It was included that smoking, family his-
tory of cancer and GSTM1 deletion at stage 
IV are significant risk factors of prostate 
cancer. However, GSTM1, GSTT1 and dele-
tion of both GSTM1 and GSTT1 genes do not 
contribute towards increased risk of prostate 
cancer in Pakistani population.  
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